This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Surgical Cytokines  • Drug Therapy  • Drug Therapy, Other  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Dual Roles in Antiapoptosis and Cell Repair

David W. Ho, MPhil; Zhen Fan Yang, PhD; Chi Keung Lau, MPhil; Ka Ho Tam, BSc; Jensen Y. To, Dip; Ronnie T. Poon, MS; Sheung Tat Fan, MS, MD, PhD

Arch Surg. 2006;141:1077-1084.

Hypothesis  Administration of cardiotrophin 1 (CT-1) can treat experimental fulminant hepatic failure (FHF).

Design  Rat model with FHF induced by D-galactosamine (D-gal).

Setting  Fulminant hepatic failure is a rapidly progressive disease that lacks effective nonsurgical treatment. Cardiotrophin 1 is a member of the interleukin 6 family that can protect cells from damage in some animal disease models.

Animals  A rat model of FHF was induced by an intraperitoneal injection of D-gal (1.4 g/kg of body weight). Cardiotrophin 1 was administered at different time points after D-gal injection.

Results  Administration of CT-1 at 12 and 18 hours had a survival rate of 80% (12/15) and 70% (7/10), respectively, which was significantly higher than that of nontreatment (28% [5/18]). In addition, improvement of liver histologic findings, shortening of activated clotting time, and decrease in serum levels of total bilirubin and alanine aminotransferase were detected with CT-1 treatment. Administration of CT-1 decreased apoptotic cells and increased Ki-67 cells in the liver tissues. In vitro, CT-1 administration significantly decreased apoptotic cells and sequentially down-regulated the expression of proapoptotic molecules and up-regulated the expression of antiapoptotic molecules at different culture periods. D-galactosamine culture induced morphologic damage in a hepatocyte cell line, which was greatly improved by CT-1 administration. In addition, CT-1–treated cells demonstrated increased expression of glycoprotein 130 and up-regulation of cyclin D1 and heat shock protein 90.

Conclusion  Cardiotrophin 1 may improve the outcome of D-gal–induced FHF through its effects on antiapoptosis and cell repair.

Author Affiliations: Centre for the Study of Liver Disease and Department of Surgery, The University of Hong Kong.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Therapeutic Potential of Cardiotrophin 1 in Fulminant Hepatic Failure—Invited Critique
E. Christopher Ellison and Ginny L. Bumgartner
Arch Surg. 2006;141(11):1084.
EXTRACT | FULL TEXT